ImmunityBio's ANKTIVA Gains UK Approval In Bladder Cancer Treatment
8/7 03:52
(RTTNews) - ImmunityBio Inc. (IBRX) announced that the UK Medicines and Healthcare products Regulatory Agency or MHRA has granted marketing authorization for ANKTIVA (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) for the treatment of certai...